There’s a study circulating right now on nerve blocking and scar-free skin regeneration – the mechanism being that certain innervation signals are actively suppressing regeneration, not just passively absent. Blocking those signals (botox-like compounds) lets tissue regrow closer to the fetal pattern. Worth comparing to what most of us are actually running for tissue repair, bc the mechanism class is different in a way that matters. BPC-157, TB-500, GHK-Cu: additive mechanisms These work by adding signals – upregulating growth factors, promoting angiogenesis, modulating inflammation. The assumption is the regenerative machinery is present but needs more input. BPC’s nitric oxide pathway and GHK-Cu’s matrix remodeling effects both fit that frame. Nerve-blocking approach: subtractive mechanism The innervation research is saying the limiting factor isn’t insufficient signal – it’s active inhibition from nerve activity. If that holds, stacking more growth factor input doesn’t address the actual bottleneck. You’re amplifying while the brake is still engaged. Are these complementary or redundant? My read is probably complementary, if the research replicates in humans, which it hasn’t. The inhibitory nerve signal problem is upstream of where BPC and GHK operate. But I’d want to see non-rodent data before factoring this into any protocol decisions – the fetal healing analogy is compelling, and rodent wound healing models have a poor translation track record. What I’m actually watching: whether the nerve-blocking effect requires systemic delivery or can be done locally. Sub-dermal botox at wound sites is already done clinically for scar reduction, mostly anecdotal. If the mechanism is local and titratable, the delivery chain question gets more interesting than the efficacy debate. The mechanism is plausible. The human data is basically nothing yet. I’d hold off on doing anything with this until there’s at least one non-rodent signal.
Worth pulling apart, because the research being referenced here is almost entirely cutaneous - dermal wound healing, where innervation density is high enough to make nerve inhibition a meaningful bottleneck. Rotator cuff, tendon, ligament: different geometry, different vascular supply, and that “brake still engaged” argument doesn’t map cleanly across tissue types without target-specific data to support it. I’ve been tracking BPC post-rotator cuff repair for exactly this reason - mechanism assumptions from skin research don’t always hold in hypovascular musculoskeletal tissue. The additive/subtractive framing is genuinely useful and I don’t want to dismiss it. But BPC’s nitric oxide pathway suppresses pro-inflammatory cascades too, not just amplifies angiogenesis. The mechanism categories are messier than they look when you move off the dermal model.
The hypovascular point is the thing worth holding onto from this: if angiogenesis is the actual bottleneck in tendon and ligament rather than an inhibitory nerve signal, the additive mechanism framing is more defensible for MSK applications, not less. Tracking BPC post-rotator cuff repair with that distinction in mind is genuinely useful data to generate.
rodent translation here is famously bad, but “amplifying while the brake is still engaged” is the framing that’s going to live in my head the next time I’m mid-protocol - if innervation inhibition is upstream of where bpc operates, my function gains don’t tell me whether I hit ceiling or just 70% bc of a bottleneck I never touched.
Mechanotransduction is the variable sitting outside this whole framing that I keep returning to for MSK specifically. Both the additive mechanism camp and the nerve-blocking inhibition angle assume the limiting factor is biochemical. But in tendon, proper collagen fiber alignment depends on mechanical loading signals that neither pathway addresses. My physio made this point early in my rotator cuff recovery: vascular supply matters, growth factor input matters, but w/o progressive load, type III collagen doesn’t remodel toward type I, and you end up with structurally weaker tissue regardless of what you’re running. I did a solo BPC run post-repair and logged ROM throughout, but I genuinely can’t separate what the peptide contributed from what the structured loading program did concurrently. That’s the confounder nobody names in these mechanism comparisons. The mechanical environment is a variable too, not just the biochemistry - and in hypovascular tissue where load is how you drive remodeling, it might be the primary one.
For skin specifically, the additive vs. subtractive framing is well-constructed, because that’s the tissue the innervation research studied. imo The problem is “the brake is still engaged” gets used as if neural inhibition is the rate-limiting step across all tissue types. Tendon and ligament repair is typically bottlenecked by collagen organization and vascular penetration, not by active neural suppression of regeneration. BPC’s fibroblast proliferation and angiogenesis effects aren’t competing with a nerve-blocking intervention in those tissues, which means the complementary case may be narrower than it sounds.
edit: forgot to add
What the framing nails is acute wound healing. The “need more signal” vs “signal is being blocked” distinction is genuinely clarifying. Where I’d push back is that it assumes neural density that skin has and chronic musculoskeletal tissue often doesn’t.
Tendons are hyponeural by design, and a joint that’s been grinding for years even more so. The “brake still engaged” model may not apply to tendon and cartilage repair the same way it applies to dermis. BPC’s nitric oxide pathway also crosses into neural signaling territory, so calling it purely additive may be neater than the mechanism warrants.
sub-dermal botox for scar reduction isn’t purely anecdotal - there are small RCTs in keloid and burn patients, and enough plastic surgeons use it routinely that the local delivery question is already partially answered for skin, which means the actual unknown is whether the inhibitory innervation mechanism is the operative one or just a passenger effect in those outcomes.
“whether the nerve-blocking effect requires systemic delivery or can be done locally” is kind of downstream of a prior question: do the target tissues even have enough innervation for this suppression mechanism to be load-bearing. skin wounds, yes. tendons, no. labrums, definitely not. most people running BPC or TB-500 are targeting hyponeural, hypovascular structures where the brake the OP is describing may not actually exist in the first place. the additive vs subtractive framing is probably real for dermal scarring and a lot less relevant for the musculoskeletal repairs most of us are actually running these for.
the additive/subtractive framing is clean and I’d mostly agree with it, but “upstream of where BPC operates” is doing a lot of work. BPC’s effects on nitric oxide signaling aren’t purely downstream growth factor stuff - there’s decent animal data on direct neural interaction, including vagal nerve effects. so the assumption that nerve-blocking approaches and BPC occupy cleanly separate rungs of the cascade might be wrong. could be more overlap than the framework suggests, which cuts both the complementarity argument and the redundancy concern.
The “inhibitory nerve signal is upstream of BPC and GHK” framing is worth pushing back on, because it assumes a clean hierarchy that probably doesn’t exist. Skin is densely innervated; the nerve-blocking mechanism may matter there. But for hyponeural tissue like tendons and labrums, the neural suppression angle carries a lot less weight by design. BPC’s angiogenesis effect is arguably more load-bearing in those structures precisely because vascularization is the actual limiting factor, not innervated signal suppression. So “complementary” might be right for skin repair, but the framing doesn’t port cleanly to musculoskeletal use cases without target-specific data.